Genentech, Inc.

Array Biopharma Inc.

Rapt Therapeutics, Inc.

Warner-lambert Company

Pfizer Corporation

Rqx Pharmaceuticals, Inc.

University of California

Genetech, Inc.

Escape Bio, Inc.

F. Hoffmann-la Roche Ag

Jacob Bradley Schwarz

Huifen Chen

James F Blake

Peter J Mohr

Li Ren

David A Moreno

John Joseph Gaudino

Mark Joseph Chicarelli

David Juergen Wustrow

Lewis J Gazzard

Mikhail Zibinsky

John Michael Ketcham

Kirk D Robarge

Maureen Kay Reilly

Adam Wade Cook

Andrew T Metcalf

Kevin W Hunt

Brad Newhouse

Jack Maung

Indrani W Gunawardana

Andrew John Thorpe

Eli M Wallace

Tony P Tang

Wendy Lee

Yu Jiang

Christopher John O'Donnell

James John Crawford

Prasuna Paraselli

Po-Wai Yuen

Robert Higuchi

Matthew Volgraf

Paul Gibbons

Elisia Villemure

Randall James Gallaschun

Avi J Ashkenazi

Fei Wang

Gabrielle R Kolakowski

Lawrence D Wise

Steven Armen Boyd

Po-wai Yuen

Justin Stephen Bryans

Georgette M Castanedo

Allison L Marlow

Hunter Paul Shunatona

Thomas R Belliotti

Albert W Garofalo

Erik James Hicken

Emily J Hanan

Daniele Andreotti

Nicole Blaquiere

Kwong Wah Lai

Akinori Okano

Cuong Q Ly

Rustam Ferdinand Garrey

Aihe Zhou

Jeffrey J Jackson

Parcharee Tivitmahaisoon

Ashkaan Younai

Jonas Grina

Omar Robles-Resendiz

Michael Lyon

Allen A Thomas

Dennis X Hu

Augustine Tobi Osuma

Paul Robert Leger

Norman Lloyd Colbry

Paul D Johnson

Guosheng Wu

Michael F T Koehler

Marie-Gabrielle Braun

Joachim Rudolph

Peter Andrew Smith

Mark Stephen Plummer

Grant Masaaki Shibuya

Tucker Curran Roberts

Timothy Thomas Curran

Anton Shakhmin

Stéphane De Lombaert

Toby Jonathan Blench

Ramsay Beveridge

Barbara Eileen Segelstein

Nancy Sue Barta

Berenger Biannic

Robert J Kaus

Huiyong Hu

Benjamin Douglas Sellers

Christopher Stephen Siedem

Ji Zhang

Philippe Bergeron

Anton Franz Joseph Fliri

Omar Robles

Jiang Yu

Jean-Philippe Leclerc

Gene Cutler

Yongsheng Chen

Samuel S Kintz

Steven Mark Wenglowsky

Robert Michael Schelkun

Jim Blake

Disclosed herein, inter alia, are compounds and methods of use thereof for the modulation of certain chemokine receptor activity.

Chemokine receptor modulators and uses thereof

Described herein are phenoxy-pyridyl-pyrimidine compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I structure or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Phenoxy-pyridyl-pyrimidine compounds and methods of use

The present invention is directed to indazole and azaindazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.

Indazoles and azaindazoles as LRRK2 inhibitors

Disclosed herein, inter alia, compounds and methods of use thereof for the modulation of USP7 activity.

Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof

Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.

Macrocyclic broad spectrum antibiotics

Disclosed herein are pyrozolo-pyrimidin-amino-cycloalkyl compounds, analogs thereof, pharmaceutical compositions comprising thereof and therapeutic uses therefor.

Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses

Described herein are pyrimidinyl-pyridyloxy-naphthyl compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I or I' structure: 

Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating IRE1-related diseases and disorders

The present invention relates to certain thiazolopyrimidinone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.

Thiazolopyrimidinones and methods of use thereof

Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. 

Serine/threonine kinase inhibitors

Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. 

Growing community of inventors

South San Francisco, CA, United States of America

Jacob Bradley Schwarz